Pulmatrix (NASDAQ:PULM) Now Covered by StockNews.com

Equities research analysts at StockNews.com started coverage on shares of Pulmatrix (NASDAQ:PULM) in a research note issued to investors on Thursday. The firm set a “hold” rating on the biotechnology company’s stock.

Pulmatrix Trading Down 0.3 %

Shares of NASDAQ:PULM opened at $5.78 on Thursday. The company has a 50 day moving average of $3.89 and a 200-day moving average of $2.69. The firm has a market cap of $21.10 million, a P/E ratio of -2.19 and a beta of 1.54. Pulmatrix has a twelve month low of $1.55 and a twelve month high of $8.44.

Pulmatrix Company Profile

Pulmatrix, Inc, a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States. The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.